Skip to content

Clinical trial of an Ayurveda Intervention

Evaluation Of The Immuno-Stimulatory Potential (Shareera Bala) Of An Ayurveda Management Protocol In Cohort Of Dda Resident Of Gautampuri - An Exploratory Clinical Study

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/026103
Enrollment
800
Registered
2020-06-24
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Samshamani Vati 500 mg bid: Samshamani Vati 500 mg bid after food with water for 8 weeks Control Intervention1: conventional medicine preventive guidelines: Only following conventional

Sponsors

All India Institute of Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.DDA residents, Gautampuri of either sex aged 19-60 years 2.Agrees not to self-medicate with chloroquine, hydroxychloroquine or other potential antivirals. 3.Individuals agree to give consent for participation

Exclusion criteria

Exclusion criteria: 1.Individuals with chronic comorbid conditions which has affected the Bala of the Individual. 2.Already suffering with severe respiratory allergies and other conditions which may create bias in the outcome results 3.Individuals found positive for COVID 19 during the course of medication. Defined as: temperature > 38 Celsius; cough; shortness of breath; sore throat; or, if available (not required), positive confirmatory testing for COVID-19 4.Previously diagnosed with COVID-19 5.Subjects on other prophylactic medications. 6.Concurrent condition that in the investigatorâ??s opinion would jeopardize compliance with the protocol.

Design outcomes

Primary

MeasureTime frame
1.Improvement in Bala of an individual 2.Immuno-stimulation leading to non-development of symptoms of CoVID-19 in risk population exposed to infected individuals. Timepoint: Baseline, After 30, 60 and 90 days

Secondary

MeasureTime frame
Improvement in Quality of life(Sf-36 proforma will be used)Timepoint: 4 week

Countries

India

Contacts

Public ContactDr Vittal Huddar

All India Institute of Ayurveda

dr.vghuddar@aiia.gov.in9986697942

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026